Open-Label Extension Study to Evaluate the Efficacy and Safety of FG-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients With Chronic Kidney Disease

Trial Profile

Open-Label Extension Study to Evaluate the Efficacy and Safety of FG-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients With Chronic Kidney Disease

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors FibroGen
  • Most Recent Events

    • 15 Apr 2016 Study design is changed from observational to Interventional as per ClinicalTrials.gov.
    • 15 Apr 2016 Planned number of patients changed from 150 to 50.
    • 15 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top